Related Experiment Video
Updated: Jun 28, 2026
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
HDAC3 in Alzheimer's Disease: established evidence, unresolved questions, and translational priorities
Jieren Luo1, Xueyi Wu1, Donglin Jiang1
1Pediatric Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Children and Adolescents' Health and Diseases, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Department of Anesthesiology, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China.
Insights
Histone deacetylase 3 (HDAC3) is linked to Alzheimer's disease (AD) pathology. Further research is needed to clarify its role and therapeutic potential in AD treatment.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Histone deacetylase 3 (HDAC3) is increasingly associated with Alzheimer's disease (AD).
- Its exact role in AD pathogenesis and its potential as a therapeutic target are not fully understood.
Purpose of the Study:
- To critically review the existing evidence linking HDAC3 to AD.
- To identify uncertainties and future research directions for translating findings into clinical applications.
Main Methods:
- Literature review of studies on HDAC3 in AD.
- Analysis of data concerning HDAC3's involvement in amyloid-beta accumulation, Tau pathology, neuroinflammation, and synaptic dysfunction.
- Evaluation of translational challenges and limitations in current research.
Main Results:
- Evidence links HDAC3 to key AD pathologies, but causal relationships are weak.
- Inconsistent findings across cell types and limited human brain validation exist.
- Significant translational hurdles include inhibitor selectivity, brain penetration, and safety concerns.
Conclusions:
- HDAC3's central role in AD pathways is not established.
- Future progress requires human evidence, cell-type specific studies, and rigorous pharmacological validation.
- A clearer roadmap is needed to assess HDAC3 as a viable therapeutic target for AD.
Abstract:
Histone deacetylase 3 (HDAC3) is increasingly implicated in Alzheimer's disease (AD), yet its precise pathogenic role and therapeutic value remain unresolved. This mini-review critically examines the current evidence for HDAC3 in AD, with a focus on what is established, what remains uncertain, and what is needed for translation. We review the data linking HDAC3 to amyloid-β (Aβ) accumulation, Tau pathology, neuroinflammation, and synaptic dysfunction, while highlighting key limitations in the field, including weak causal evidence, inconsistent cell type-specific findings, insufficient human brain validation, and the lack of proof that HDAC3 serves as a central mechanistic node across AD-related pathways. We also discuss major translational challenges, including poor inhibitor selectivity, uncertain brain penetrance, potential safety concerns, and the absence of standardized preclinical benchmarks. We propose that future progress will require human evidence, cell type-specific causal studies, integrated mechanistic models, and more rigorous pharmacological validation. Together, these considerations define a clearer roadmap for evaluating HDAC3 as a biologically credible and clinically actionable target in AD.
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
01:22Alzheimer's Disease: Treatment
01:29Alzheimer Disease l: Introduction
01:22Dementia l: Introduction
01:21Huntington Disease l: Introduction